Get in touch
Close

Contacts

Sarvodaya Hospital,
Sector 8,
Faridabad, Haryana, India

+ (91) 9355258181

info@theranos.care

Actinium-225 PSMA Therapy: A New Hope for Prostate Cancer Patients in India

actinium 225 therapy in India

If you or your loved one is living with advanced prostate cancer and have already tried several treatments like chemotherapy or Lutetium-177 therapy, there’s a new and promising option available: “Actinium-225 PSMA therapy”.

What Is Actinium-225 Therapy?

This treatment uses a special type of radiation called “alpha therapy”. It’s designed to find and destroy cancer cells while causing very little harm to healthy parts of your body. Think of it as a “guided missile” that targets cancer with great precision.

It’s especially helpful for:

Patients whose cancer has come back or spread after other treatments

Tumors that no longer respond to common therapies

Cases where the cancer is small and hard to detect with scans

Now Available at Sarvodaya Hospital, Faridabad

Sarvodaya Hospital has become one of the best theranostics center in India to offer this advanced treatment. Guided by Dr. Swagat Dash, an expert in nuclear medicine and a recognized global ambassador for cancer care, the hospital is making this world-class therapy available to more patients—including those who may need financial help.

Thanks to their partnership with the “Oncidium Foundation”, eligible patients at Sarvodaya Hospital may also receive support for treatment costs. This ensures that “cutting-edge cancer care is within reach”, not just for a few, but for all who need it.

A Complete Approach to Cancer Care

Along with Actinium-225, Sarvodaya Hospital also offers:

Terbium-161 therapy for patients of Neuroendocrine Tumor or Advanced Prostate Cancer who didn’t benefit from earlier treatments

FAPI therapy in Delhi NCR, India for refractory cancers like Sarcoma, Breast, Ovary, Lung etc- Other advanced nuclear therapies to treat host of other complex cancers

Leave a Reply

Discover more from Theranostics Clinic

Subscribe now to keep reading and get access to the full archive.

Continue reading